Future treatment options for Gram-positive infections--looking ahead

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
E Barton, A MacGowan

Abstract

Multidrug-resistant Gram-positive infections remain a significant therapeutic problem, especially those due to Staphylococcus aureus. Antimicrobial choice is only one aspect of the management of these infections. New immunotherapies, exploitation of novel antibiotic targets, topical therapies and new drug delivery systems may have a future role in the management of S. aureus infection. At present, injectable antimicrobials are the main area of drug development and clinical interest. Since 1999, five anti-Gram-positive agents (moxifloxacin, quinupristin-dalfopristin, linezolid, daptomycin and tigecycline) have become available in the EU. At present, three other anti-Gram-positive agents are being considered by the European Medicines Agency (ceftobiprole, gemifloxacin and iclaprim), and a further four have completed phase III clinical trials (ceftaroline, dalbavancin, oritavancin and telavancin). The antibacterial spectra of these agents, their in vitro potencies, bactericidal activities and pharmacokinetics are well known. The safety profiles for those agents that have received regulatory approval and entered clinical practice are also firmly established. Most of the agents are pharmacodynamically promising and effective in clin...Continue Reading

References

Jun 8, 2002·Diagnostic Microbiology and Infectious Disease·Charles H BallowUNKNOWN North American ZAPS Research Group
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·Barry H DvorchikRobert D Arbeit
Feb 20, 2004·Diagnostic Microbiology and Infectious Disease·Jennifer M StreitRonald N Jones
Feb 27, 2004·The Journal of Antimicrobial Chemotherapy·Jennifer M StreitHelio S Sader
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Anne Schmitt-HoffmannErhard Weidekamm
Sep 8, 2004·Current Opinion in Pharmacology·Françoise Van Bambeke
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J P ShawS Barriere
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·Gopal MuralidharanSteven Troy
Jan 11, 2005·Current Opinion in Infectious Diseases·Gregory M Anstead, Aaron D Owens
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Tatiana BogdanovichPeter C Appelbaum
Jul 4, 2006·The Journal of Antimicrobial Chemotherapy·Kenneth N Agwuh, Alasdair MacGowan
Oct 4, 2007·Dermatology : International Journal for Clinical and Investigative Dermatology·Arnold P OranjeUNKNOWN TOC100224 Study Team
Dec 21, 2007·Seminars in Respiratory and Critical Care Medicine·Peter K Linden
Dec 22, 2007·Expert Review of Medical Devices·Rajiv Dhand, Harjyot Sohal
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter E PertelJeff Alder
Jul 1, 2008·The Journal of Antimicrobial Chemotherapy·Shekman L WongMichael R Goldberg
Aug 14, 2008·The Journal of Antimicrobial Chemotherapy·Alasdair P MacGowan
Aug 13, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nadine ShehabDaniel S Budnitz
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·Russell HopeUNKNOWN BSAC Working Parties on Resistance Surveillance
Oct 22, 2008·BMJ : British Medical Journal·Drew ProvanUNKNOWN UK Immunoglobulin Expert Working Group
Mar 18, 2009·Antimicrobial Agents and Chemotherapy·Helio S SaderRonald N Jones
Sep 10, 2009·Antimicrobial Agents and Chemotherapy·Francis F ArhinDaniel F Sahm

❮ Previous
Next ❯

Citations

Jun 7, 2013·BMC Infectious Diseases·Carolin A KreisThomas Fuchs
Dec 18, 2010·Future Microbiology·Rasmus V RasmussenNiels E Bruun
Nov 3, 2010·La Revue de médecine interne·M LafaurieUNKNOWN Groupe des référents en infectiologie d'Île-de-France (GRIF)
Aug 24, 2010·International Journal of Antimicrobial Agents·Emilio Bouza, Almudena Burillo
Dec 24, 2013·American Journal of Infection Control·Susan B GlickStephen G Weber

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.